Ropes & Gray Advised Black Diamond Therapeutics On Global Licensing Agreement With Servier

Ropes & Gray advised Black Diamond Therapeutics on global licensing agreement with Servier

Ropes & Gray advised Black Diamond Therapeutics on a global licensing agreement with French pharmaceutical company Servier for the development and commercialization of BDTX-4933, a therapy designed to target RAS and RAF alterations in solid tumors.

The collaboration aims to advance BDTX-4933 across multiple indications, including non-small cell lung cancer and other solid tumors. Under the terms of the agreement, Servier will assume responsibility for global development and commercialization of the therapy. Black Diamond will receive an upfront payment of $70 million and may earn up to $710 million in milestone payments, in addition to tiered royalties on global net sales.

The Ropes & Gray team was led by Abigail Gregor (Life Sciences Licensing Partner) and Esteban De La Torre (IP Transactions Associate), with support from Lisa Kaltenbrunner (Litigation & Enforcement Partner) and Vincenzo Volpe (Litigation & Enforcement Associate).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.